CRP and colorectal cancer: We studied longitudinally inflammatory reactions and serum C-reactive protein (S-CRP) levels in 52 colorectal cancer patients treated with a median of six 3-weekly cycles of raltitrexed 1.5–3.0 mg m−2 combined with oral carmofur (1-hexylcarbomoyl-5-fluorouracil) 300–400 mg m−2 on cycle days 2–14.